Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
PT-141
FDA-approved melanocortin agonist (Vyleesi) for HSDD in premenopausal women. Prescription only.
Tier Alow risk
02· Subject
Melanotan II
Unlicensed broad melanocortin agonist with pigmentation and sexual side-effect profiles. Highest compliance risk.
Tier Chigh risk
01 · At a glance
| Decision factor | PT-141 | Melanotan II | Oxytocin |
|---|---|---|---|
| Primary fit | sexual health & libido research where you want a clear starting point | skin & hair and sexual health & libido comparisons | sexual health & libido and anxiety & mood comparisons |
| Evidence | Tier A | Tier C | Tier A |
| Risk | low | high | med-high |
| Experience level | advanced | advanced | advanced |
| Budget tier | premium | budget | mid |
| Administration route | subcutaneous | subcutaneous | intranasal, intravenous |
02 · Use case & timing
| Decision factor | PT-141 | Melanotan II | Oxytocin |
|---|---|---|---|
| Goal fit | Sexual Health & Libido | Skin & Hair, Sexual Health & Libido | Sexual Health & Libido, Anxiety & Mood |
| What users compare it for | Improved sexual desire in premenopausal women with acquired generalized HSDD. | Pigmentation changes (tanning); sexual arousal effects. NOT a controlled therapeutic product. | Social cognition, bonding, anxiety modulation effects in research settings. |
| Onset timeline | Designed for acute/as-needed effect within an hour; BP effects peak in hours post-dose. | Pigmentation changes can occur quickly; adverse events can be acute. | Acute effects studied within hours post-dose; mixed efficacy across conditions. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | PT-141 | Melanotan II | Oxytocin |
|---|---|---|---|
| Adverse effects | Nausea, flushing, injection site reactions, headache, vomiting. BP elevation. | FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns. | Generally minimal at trial doses; vulnerable populations require caution. |
| Contraindications | Uncontrolled hypertension, known cardiovascular disease. Avoid co-use with oral naltrexone-containing products. | High risk across the board; unlicensed and unapproved. | Rx product; clinical supervision required. |
| Interaction notes | Slowed gastric emptying impacts absorption of concomitant oral meds. Clinically meaningful interaction with oral naltrexone. | Unknown; risk may increase with UV exposure behaviors and stimulant-like exposures. | No uniform interaction map; treat as Rx/clinical research context. |
| Regulatory status | Prescription-approved | Not approved | Prescription-approved |
| FDA flag | No current flag noted | FDA compounding caution | No current flag noted |
| WADA status | Not listed | Status unclear | Not listed |
04 · Age & monitoring
| Decision factor | PT-141 | Melanotan II | Oxytocin |
|---|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54, 55-64 | No age guidance yet | No age guidance yet |
| Life-stage note | Adult sexual-health use case with strongest fit before later-life cardiovascular burden becomes a larger concern. | Not yet documented | Not yet documented |
| Monitoring burden | medium | Not specified | Not specified |
| Follow-up cadence | Review tolerance early and reassess if use becomes frequent. | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | PT-141 | Melanotan II | Oxytocin |
|---|---|---|---|
| Typical cycle cost | €27.29 | $80.00 | No reliable estimate yet |
| Estimated monthly cost | €27.29 | $53.33 | No reliable estimate yet |
| Cost confidence | High confidence | High confidence | No estimate |
06 · Before you buy
| Decision factor | PT-141 | Melanotan II | Oxytocin |
|---|---|---|---|
| Tracked vendor listings | 3 listings | 3 listings | 1 listing |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. | Tracked product pages are available, which makes it easier to review the listing before you click out. |
| Stack-friendly? | Better as a standalone decision | Usually stack-friendly | Better as a standalone decision |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.